𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Changing shape of disease: Nonalcoholic fatty liver disease in Crohn's disease—A case series and review of the literature

✍ Scribed by Christopher E. McGowan; Patricia Jones; Millie D. Long; A. Sidney Barritt IV


Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
90 KB
Volume
18
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

✦ Synopsis


Background: With improvements in therapy for inflammatory bowel disease (IBD) and changes in the prevalence of obesity, the phenotype of Crohn's disease (CD) is changing. These changes may herald an increase in the incidence of nonalcoholic fatty liver disease (NAFLD) in this population.

Methods: Over a 10-month period we identified seven patients with CD who required liver biopsy for elevated liver function tests (LFTs), with an ultimate diagnosis of NAFLD. We performed a retrospective chart review and literature search to identify relevant data on NAFLD and CD. Specifically, we abstracted prior and current IBD-related medication exposures, disease severity, and the presence of typical comorbidities associated with NAFLD.

Results:

We describe seven patients with CD and biopsy-proven NAFLD. The majority of these patients were overweight or obese, had quiescent CD, and were more likely to be receiving a tumor necrosis factor-alpha inhibitor. Review of the literature produced a total of 29 articles describing NAFLD in IBD patients, primarily restricted to historical autopsy and surgical series. Limited contemporary studies highlight the rising prevalence of NAFLD in treated IBD populations.

Conclusions: NAFLD is increasing in incidence and prevalence among the general population. With improvements in therapy, NAFLD is likely increasing among the CD population as well. When evaluating an IBD patient with abnormal LFTs, clinicians need to consider NAFLD. NAFLD may impact IBD management in the future if therapeutic modalities are limited due to elevated LFTs. Further, patients should be monitored for excessive weight gain and counseled regarding healthy dietary and exercise habits.


📜 SIMILAR VOLUMES


Progress in understanding the pathogenes
✍ Richard H. Moseley 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 2 views

The pathogenesis of nonalcoholic steatohepatitis (NASH) is poorly defined. Feeding mice a diet deficient in methionine and choline (MCD diet) induces experimental NASH. Osteopontin (OPN) is a Th1 cytokine that plays an important role in several fibroinflammatory diseases. We examined the role of OPN

In vivo assessment of liver cell apoptos
✍ Anna Wieckowska; Nizar N. Zein; Lisa M. Yerian; A. Rocio Lopez; Arthur J. McCull 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 344 KB 👁 1 views

In patients with nonalcoholic fatty liver disease (NAFLD), a liver biopsy remains the only reliable way to differentiate simple steatosis from nonalcoholic steatohepatitis (NASH). Noninvasive methods are urgently needed. Increasing evidence suggests hepatocyte apoptosis is a key mediator of liver in

Pregnancy in Parkinson's disease: A revi
✍ Peter Hagell; Per Odin; Ellen Vinge 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB

Pregnancy is rare in Parkinson's disease (PD). In the literature on studies of antiparkinsonian drugs in animals during pregnancy, there are reports on malformations of the skeletal and circulatory system. However, the majority of studies in animals have not shown any teratogenicity. Amantadine has